论文部分内容阅读
2011年10月,欧盟委员会批准了Lilly公司的培美曲塞二钠注射剂(disodium pemetrexed/Alimta)一新适应证,即单药用于在接受培美曲塞二钠联合顺铂(cisplatin)一线治疗期间疾病没有进展的进展期非鳞癌非小细胞肺癌患者的继续维持治疗,以进一步改善疾病无进展存活时间并获得更高的总存活期。这是欧盟委员会首次批准一个化疗药物用作肿瘤患者继续维持
In October 2011, the European Commission approved a new indication from Lilly’s disodium pemetrexed / Alimta that the monotherapy was used to treat patients receiving peptitrexed disodium combined with cisplatin Patients with advanced nonsquamous non-small cell lung cancer who have had no progression of disease during treatment will continue their treatment to further improve their progression-free survival and to achieve a higher overall survival. This is the first time the European Commission has approved a chemotherapeutic drug for use as a cancer patient